FGF R2 Antibody Summary
Synthetic peptide: KLPQYPHIGSVKT conjugated to KLH by a Glutaraldehyde linker, corresponding to amino acids 809-821 of the cytoplasmic region of Human FGFR2.
FGFR-2. No reaction with human FGFR-1 and FGFR-3 is detected.
Mouse (92%), Rat (92%). Backed by our 100% Guarantee.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
- Western Blot 0.25-0.5 ug/ml
- Immunohistochemistry 1:10-1:500
- Immunohistochemistry-Paraffin 2-4 ug/ml
Although not tested this antibody may be useful in Immunohistochemistry-Frozen.
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
10mM PBS (pH 7.4) and 1.0% BSA
15mM Sodium Azide
Immunogen affinity purified
Alternate Names for FGF R2 Antibody
- CD332 antigen
- craniofacial dysostosis 1
- EC 2.7.10
- EC 188.8.131.52
- FGF R2
- fibroblast growth factor receptor 2
- Jackson-Weiss syndrome
- Keratinocyte growth factor receptorreceptor like 14
- soluble FGFR4 variant 4
Fibroblast growth factors (FGFs) are members of a large family of structurally related heparin binding polypeptides (17-38kD) that are potent physiological regulators of growth and differentiation for a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They have also been implicated in pathological conditions such as tumorigenesis and metastasis. The FGF family consists of at least seventeen members designated FGF1 through FGF17. To date, four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg, cek-1], FGFR2 [bek, cek-3], FGFR3 [cek-2] and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported. Soluble, secreted8 or possibly cleaved9 forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110-150 kD proteins that are constructed of an extracellular ligand binding region with either two or typically three immunoglobulin (Ig)-like domains and an eight amino acid 'acidic box', a transmembrane region and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of all FGFRs is confined to the extracellular Ig-like domains 2 and 3.
FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind several of the FGFs with a similar affinity. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGFs binding to cellular FGFRs depends on, or is markedly facilitated by the low-affinity interaction of FGFs with the polysaccharide component of cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR- 2 is highly expressed in developing human tissues including the brain (preferentially in glial cells), choroid plexus, skin, lung, kidney and bone. It is widely expressed in many adult human and animal tissues. It may be found in several anchorage-dependent cells, such as normal and malignant breast cancer cells. Crouzon as well as other craniosynostosis syndromes (e.g. Pfeiffer's, Apert's, Jackson-Weiss'), disorders of human skeletal development, have been shown to be the result of mutations in the extracellular domain of FGFR2.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed
for 1 year from date of receipt.
Customers Who Viewed This Item Also Viewed...
Species: Hu, Mu, Rt
Applications: WB, Flow, IP, CyTOF-ready
Applications: WB, IHC, ICC
Applications: WB, IHC
Species: Hu, Mu, Rt, Mk
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-P
Applications: WB, Flow, IHC, IP, CyTOF-ready, ELISA(Cap), ELISA(Det), ICC, ELISA(Sta)
Applications: IHC, IHC-P
Species: Hu, Mu, Xp
Applications: WB, IHC, IHC-Fr, IHC-P, IP, IF
Species: Hu, Mu
Applications: WB, Simple Western, Flow, IHC, CyTOF-ready, ICC
Species: Hu, Mu, Rt
Applications: WB, IHC, IHC-P
Publications for FGF R2 Antibody (NB200-642) (0)
There are no publications for FGF R2 Antibody (NB200-642).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for FGF R2 Antibody (NB200-642) (0)
There are no reviews for FGF R2 Antibody (NB200-642).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
- 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for FGF R2 Antibody (NB200-642) (0)
Positive Control Lysate(s)
Additional FGF R2 Products
Bioinformatics Tool for FGF R2 Antibody (NB200-642)
Discover related pathways, diseases and genes to FGF R2 Antibody (NB200-642). Need help?
Read the Bioinformatics Tool Guide
for instructions on using this tool.
Blogs on FGF R2